Oslif Breezhaler (Indacaterol)

Indacaterol, the active ingredient in Oslif Breezhaler, is a Long‑acting β2‑adrenergic agonist (LABA) presented as a dry‑powder inhalation formulation for inhalation use. It provides maintenance bronchodilation for patients with chronic obstructive pulmonary disease (COPD).

GNH USA supplies Oslif Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indacaterol is a long‑acting β2‑agonist indicated for maintenance therapy in chronic obstructive pulmonary disease and related conditions.

- COPD: improves lung function and reduces the frequency of exacerbations. - Chronic bronchitis: provides sustained bronchodilation to ease airflow limitation. - Emphysema: helps maintain airway patency and supports symptom control.

Indacaterol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Cough: mild to moderate irritation of the throat. - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: occasional mild headache. - Throat irritation: sensation of dryness or soreness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Hypersensitivity reactions: rash, itching, or swelling. - Angioedema: swelling of the face, lips, or tongue. - Cardiovascular events: tachyarrhythmia or significant hypertension.

Before prescribing indacaterol, clinicians should consider patient‑specific factors and monitor for potential risks.

- Cardiovascular assessment: evaluate for existing heart disease before use. - Paradoxical bronchospasm: advise patients to seek immediate help if breathing worsens. - Hepatic impairment: use with caution in severe liver disease. - Electrolyte balance: monitor potassium levels, especially if diuretics are used. - β‑blocker use: avoid concurrent non‑selective β‑blockers as they may reduce efficacy. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Indacaterol can interact with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Non‑selective β‑blockers: may antagonize bronchodilator effect and precipitate bronchospasm. - Other long‑acting β2‑agonists: increase risk of cardiovascular adverse events. - Monoamine oxidase inhibitors (MAOIs): potential for exaggerated sympathomimetic effects.

Moderate Interactions (Monitor Closely): - Inhaled corticosteroids: heightened risk of pneumonia in COPD patients. - Diuretics: may exacerbate hypokalemia, increasing arrhythmia risk. - Theophylline: possible additive stimulant effects on the heart.